Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.
Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
Authors:
Wu Y, Chen S, Yang X, [...]one or more additional authors omittedFields RC, [...]one or more additional authors omitted Chen F